WallStreetZenWallStreetZen

NASDAQ: SERA
Sera Prognostics Inc Stock

Overview
ForecastEarningsDividendOwnership
$4.25+0.11 (+2.66%)
Updated Mar 17, 2023
SERA Price
$4.25
Fair Value Price
N/A
Market Cap
$131.82M
52 Week Low
$1.10
52 Week High
$4.25
P/E
-3.76x
P/B
1.23x
P/S
216.64x
PEG
N/A
Dividend Yield
N/A
Revenue
$229.00k
Earnings
-$46.92M
Gross Margin
35.4%
Operating Margin
-20,471.18%
Profit Margin
-20,490.8%
Debt to Equity
0.09
Operating Cash Flow
-$37M
Beta
0.97
Next Earnings
Mar 22, 2023
Ex-Dividend
N/A
Next Dividend
N/A

SERA Overview

Sera Prognostics Incorporated is a women's health diagnostic company. It offers biomarker tests for improving pregnancy outcomes by testing for preeclampsia, molecular time-to-birth, gestational diabetes mellitus, fetal growth restriction, stillbirth, and postpartum depression. PreTRM, a blood-based biomarker test to predict the risk of spontaneous preterm birth in asymptomatic singleton pregnancies, was one of the company's first successes. Sera Prognostics was incorporated in 2008 and is headquartered in Salt Lake City, UT.

Zen Score

–
Industry Average (30)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how SERA scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

SERA is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
SERA is good value based on its book value relative to its share price (1.23x), compared to the US Diagnostics & Research industry average (4.1x)
P/B vs Industry Valuation
SERA is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more SERA due diligence checks available for Premium users.

Be the first to know about important SERA news, forecast changes, insider trades & much more!

SERA News

Valuation

SERA fair value

Fair Value of SERA stock based on Discounted Cash Flow (DCF)
Price
$4.25
Fair Value
$2.72
Overvalued by
56.21%
SERA is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation

SERA price to earnings (PE)

For valuing profitable companies with steady earnings
Company
-3.76x
Industry
32.57x
Market
21.81x

SERA price to book (PB)

For valuing companies that are loss-making or have lots of physical asset
Company
1.23x
Industry
4.1x
SERA is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation

SERA's financial health

Profit margin

Revenue
$87.0k
Net Income
-$10.7M
Profit Margin
-12,312.6%
SERA's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
SERA's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials

Assets to liabilities

Assets
$116.6M
Liabilities
$9.4M
Debt to equity
0.09
SERA's short-term assets ($90.84M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
SERA's short-term assets ($90.84M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
SERA's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
-$8.8M
Investing
-$6.3M
Financing
-$8.0k
SERA's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials

SERA vs Diagnostic & Research Stocks

TickerMarket Cap1d %P/EP/B
SERA$131.82M+2.66%-3.76x1.23x
PSNL$127.59M-5.86%-1.10x0.58x
ANIX$126.17M-8.93%-9.95x4.54x
BDSX$142.69M-0.54%-1.18x6.92x
NOTV$119.19M-1.27%-0.34x0.42x
View Top Diagnostic & Research Stocks

Sera Prognostics Stock FAQ

What is Sera Prognostics's quote symbol?

NASDAQ: SERA) Sera Prognostics trades on the NASDAQ under the ticker symbol SERA. Sera Prognostics stock quotes can also be displayed as NASDAQ: SERA.

If you're new to stock investing, here's how to buy Sera Prognostics stock.

What is the 52 week high and low for Sera Prognostics (NASDAQ: SERA)?

(NASDAQ: SERA) Sera Prognostics's 52-week high was $4.25, and its 52-week low was $1.10. It is currently at its 52-week high and 286.36% from its 52-week low.

How much is Sera Prognostics stock worth today?

(NASDAQ: SERA) Sera Prognostics currently has 31,016,979 outstanding shares. With Sera Prognostics stock trading at $4.25 per share, the total value of Sera Prognostics stock (market capitalization) is $131.82M.

Sera Prognostics stock was originally listed at a price of $11.90 in Jul 15, 2021. If you had invested in Sera Prognostics stock at $11.90, your return over the last 1 years would have been -64.29%, for an annualized return of -64.29% (not including any dividends or dividend reinvestments).

How much is Sera Prognostics's stock price per share?

(NASDAQ: SERA) Sera Prognostics stock price per share is $4.25 today (as of Mar 17, 2023).

What is Sera Prognostics's Market Cap?

(NASDAQ: SERA) Sera Prognostics's market cap is $131.82M, as of Mar 20, 2023.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Sera Prognostics's market cap is calculated by multiplying SERA's current stock price of $4.25 by SERA's total outstanding shares of 31,016,979.
©2023 WallStreetZen
Company
AboutBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTube
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.